SU1122220A3 - Способ получени дигидрохлоридов производных ди-0- @ -алкилглицеринов - Google Patents
Способ получени дигидрохлоридов производных ди-0- @ -алкилглицеринов Download PDFInfo
- Publication number
- SU1122220A3 SU1122220A3 SU792764751A SU2764751A SU1122220A3 SU 1122220 A3 SU1122220 A3 SU 1122220A3 SU 792764751 A SU792764751 A SU 792764751A SU 2764751 A SU2764751 A SU 2764751A SU 1122220 A3 SU1122220 A3 SU 1122220A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- cells
- dihydrochlorides
- compound
- derivatives
- obtaining
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000007868 Raney catalyst Substances 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 abstract description 7
- 229910052759 nickel Inorganic materials 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 31
- 238000012360 testing method Methods 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 230000035931 haemagglutination Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- -1 piperidino, morpholino Chemical group 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 229960001614 levamisole Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- QYRFJLLXPINATB-UHFFFAOYSA-N hydron;2,4,5,6-tetrafluorobenzene-1,3-diamine;dichloride Chemical class Cl.Cl.NC1=C(F)C(N)=C(F)C(F)=C1F QYRFJLLXPINATB-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- DMCVVFIWYIKAEJ-UHFFFAOYSA-N 4-phenylpiperidine-4-carbonitrile Chemical compound C=1C=CC=CC=1C1(C#N)CCNCC1 DMCVVFIWYIKAEJ-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000626238 Cepora Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 101800001194 Crustacean hyperglycemic hormone 2 Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- HUMHYXGDUOGHTG-HEZXSMHISA-N alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)OC1O HUMHYXGDUOGHTG-HEZXSMHISA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/44—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reduction and hydrolysis of nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/906,260 US4173641A (en) | 1978-05-15 | 1978-05-15 | Di-O-n-alkyl glycerol derivatives as immune stimulants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1122220A3 true SU1122220A3 (ru) | 1984-10-30 |
Family
ID=25422164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU792764751A SU1122220A3 (ru) | 1978-05-15 | 1979-05-14 | Способ получени дигидрохлоридов производных ди-0- @ -алкилглицеринов |
Country Status (38)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4255426A (en) * | 1979-07-09 | 1981-03-10 | Pfizer Inc. | 1-(2-Hydroxy-3-n-alkoxypropyl)-4-substituted-piperazines and piperidines |
| US4312877A (en) * | 1979-07-09 | 1982-01-26 | Pfizer Inc. | 1-(2-Hydroxy-3-n-alkoxypropyl)-4-substituted piperidines, pharmaceutical compositions, thereof and use thereof |
| US4395394A (en) * | 1979-10-26 | 1983-07-26 | Pfizer Inc. | Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
| US4310550A (en) * | 1979-10-26 | 1982-01-12 | Pfizer Inc. | Lipid amines formulated with fat or lipid emulsions as vaccine adjuvants |
| JPS60105650A (ja) * | 1983-11-14 | 1985-06-11 | Ono Pharmaceut Co Ltd | グリセリン誘導体、その製造方法及びその誘導体を含有する薬剤 |
| US4880626A (en) * | 1985-01-18 | 1989-11-14 | Mcmichael John | Immunotherapeutic methods and compositions for the treatment of diseases of viral origin, including acquired immune deficiency syndrome |
| JPS62156230A (ja) * | 1985-12-27 | 1987-07-11 | Nippon Steel Corp | 帯状物の蛇行修正方法 |
| US4842862A (en) * | 1986-07-03 | 1989-06-27 | International Minerals & Chemical Corp. | Immunostimulating agents |
| ZA899436B (en) * | 1988-12-12 | 1990-08-29 | Ciba Geigy | Piperidine derivatives |
| WO2005077963A1 (fr) * | 2004-01-16 | 2005-08-25 | Institut Superieur Agricole De Beauvais | DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes. |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2738351A (en) * | 1952-08-02 | 1956-03-13 | Bristol Lab Inc | Substituted glycerol ethers |
| US3432602A (en) * | 1967-12-20 | 1969-03-11 | Astra Ab | Oral alkyl glycerol ether improvement in radiation,radiomimetic,or cytostatic tumor therapies |
| US3943173A (en) * | 1972-11-22 | 1976-03-09 | Smithkline Corporation | 3-Alkylamino- alpha-aminomethyl-4-hydroxybenzyl alcohols |
| US4012528A (en) * | 1974-06-03 | 1977-03-15 | Smithkline Corporation | α-AMINOALKYL-3-(1,2-DIHYDROXYETHYL)-4-HYDROXY-BENZYL ALCOHOLS HAVING β-ADRENERGIC STIMULANT ACTIVITY |
| US4069223A (en) * | 1977-05-02 | 1978-01-17 | G. D. Searle & Co. | 4-Aminomethyl-1-(3,3,3-triarylpropyl)-4-arylpiperidine and derivatives thereof |
| US4166132A (en) * | 1977-08-18 | 1979-08-28 | Pfizer Inc. | Antiviral amine derivatives of glycerol and propanediols |
-
1978
- 1978-05-15 US US05/906,260 patent/US4173641A/en not_active Expired - Lifetime
-
1979
- 1979-03-12 DK DK102479A patent/DK149946C/da not_active IP Right Cessation
- 1979-03-13 IN IN173/DEL/79A patent/IN150574B/en unknown
- 1979-04-18 PH PH22379A patent/PH15256A/en unknown
- 1979-04-26 CH CH395479A patent/CH639939A5/fr not_active IP Right Cessation
- 1979-05-10 YU YU1094/79A patent/YU41156B/xx unknown
- 1979-05-11 AU AU47016/79A patent/AU513771B2/en not_active Ceased
- 1979-05-11 CA CA327,431A patent/CA1105935A/en not_active Expired
- 1979-05-14 FR FR7912175A patent/FR2426039A1/fr active Granted
- 1979-05-14 IL IL57268A patent/IL57268A/xx unknown
- 1979-05-14 HU HU79PI677A patent/HU180283B/hu not_active IP Right Cessation
- 1979-05-14 SU SU792764751A patent/SU1122220A3/ru active
- 1979-05-14 PT PT69607A patent/PT69607A/pt unknown
- 1979-05-14 AT AT0356179A patent/AT372678B/de not_active IP Right Cessation
- 1979-05-14 BE BE0/195142A patent/BE876229A/xx not_active IP Right Cessation
- 1979-05-14 GR GR59080A patent/GR72419B/el unknown
- 1979-05-14 NO NO791604A patent/NO151285C/no unknown
- 1979-05-14 ZA ZA792306A patent/ZA792306B/xx unknown
- 1979-05-14 FI FI791531A patent/FI69450C/fi not_active IP Right Cessation
- 1979-05-14 ES ES79480565A patent/ES480565A1/es not_active Expired
- 1979-05-14 PL PL1979215573A patent/PL123910B1/pl unknown
- 1979-05-14 GB GB7916722A patent/GB2021580B/en not_active Expired
- 1979-05-14 NZ NZ190444A patent/NZ190444A/xx unknown
- 1979-05-14 IT IT22664/79A patent/IT1115217B/it active
- 1979-05-14 LU LU81253A patent/LU81253A1/xx unknown
- 1979-05-14 NL NLAANVRAGE7903769,A patent/NL175524C/xx active Search and Examination
- 1979-05-14 SE SE7904216A patent/SE429966B/sv not_active IP Right Cessation
- 1979-05-14 JP JP54059019A patent/JPS5924974B2/ja not_active Expired
- 1979-05-14 GT GT197957869A patent/GT197957869A/es unknown
- 1979-05-15 DD DD79212895A patent/DD144540A5/de unknown
- 1979-05-15 DE DE2919514A patent/DE2919514C2/de not_active Expired
- 1979-05-15 AR AR276517A patent/AR221724A1/es active
- 1979-05-15 EG EG289/79A patent/EG15252A/xx active
- 1979-08-08 IE IE938/79A patent/IE48229B1/en not_active IP Right Cessation
-
1982
- 1982-12-29 JP JP57235061A patent/JPS58131947A/ja active Granted
-
1983
- 1983-11-02 SG SG654/83A patent/SG65483G/en unknown
- 1983-11-22 KE KE3354A patent/KE3354A/xx unknown
-
1984
- 1984-02-16 HK HK135/84A patent/HK13584A/xx unknown
-
1985
- 1985-12-30 MY MY96/85A patent/MY8500096A/xx unknown
Non-Patent Citations (1)
| Title |
|---|
| 1. G. Renoux et al. J. Immunol, 109, 1972, p. 761. 2.Патент СТА 2738351, кл. 260-293.4, опублик. 1956. 3.Бюпер К., Пирсон Д. Органические синтезы, ч. 1 . М., Мир, 1973, с. 477. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1122220A3 (ru) | Способ получени дигидрохлоридов производных ди-0- @ -алкилглицеринов | |
| JP3732506B2 (ja) | ワクチンアジュバント | |
| Cooper et al. | Prostaglandin production associated with the pulmonary vascular response to complement activation | |
| EP0815204B1 (en) | Method for treating tumors by alloactivated human donor lymphocytes | |
| Staneck et al. | Arenaviruses: cellular response to long-term in vitro infection with parana and lymphocytic choriomeningitis viruses | |
| PL167302B1 (en) | Method of obtaining novel 1r-cis, 1'r-cis-2,2'-(3,11-dixo-4,10-dioxatridekamethylene)-bis-(1,2,3,4 tetrahydro-6,7-dimethoxy-2-methyl-1-veratryloisoquinolinic salts | |
| Ekas Jr et al. | Sympathetic nerve function and vascular reactivity in Doca-salt hypertensive rats | |
| JPS6043351B2 (ja) | 老人医学的薬剤の製法 | |
| SU1598870A3 (ru) | Способ получени производных 1,4-дигидропиридина | |
| SU1384200A3 (ru) | Способ получени бициклических соединений или их аддитивных солей сол ной кислоты | |
| EP0194665A1 (en) | beta-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives | |
| CN113461680B (zh) | 4-羟基香豆素氮杂靛红衍生物及其制备方法和应用 | |
| SU1590041A3 (ru) | Способ получени производных 1,4-дигидропиридина | |
| EP0431125A1 (de) | Herstellungsverfahren fur humane monoklonale antikörper | |
| JPS63154663A (ja) | ３，５−ジ−タ−シヤリ−ブチル−４−ヒドロキシケイ皮酸アミド誘導体 | |
| CN117486761B (zh) | 一种含芳基的氯乙基亚硝基脲类化合物及其制备方法和应用 | |
| El-Azab et al. | Pharmacologic profile of a new antiallergic compound PRD-92-Ea | |
| JPH01500270A (ja) | ５‐ヘテロ‐またはアリール‐置換された‐イミダゾ［２，１‐ａ］イソキノリン類 | |
| Virno et al. | Action of histamine on the jugular venous pressure and cerebral circulation of the dog. Effects of antihistaminic drugs (pyrilamine and chlorpheniramine) and a histamine liberating agent (48/80 BW) | |
| US2319902A (en) | Therapeutic pressor composition and method of preparing it | |
| US4988735A (en) | Ethylene diamine active cardiovascular therapy | |
| Lovett III et al. | Suppressor cells and increased primary tumor growth rate induced by thiopental | |
| SU1001940A1 (ru) | Способ получени диагностикума | |
| SU1241993A3 (ru) | Способ получени бициклических соединений или их гидрохлоридов | |
| CN116874486A (zh) | 氨基酸修饰的s,s-七环羧酸化学合成,抗栓活性和应用 |